Abstract
Healthcare is continually evolving to meet the changing needs of twenty-first century populations whilst striving to keeping pace with medical and technological advancements. Patients and clinicians remain the constants in this evolving environment, sitting at the cutting edge of new evidence and innovation and at the coalface of clinical services which need to address the increasingly challenging health priorities we face as a society. Patients and clinicians, positioned centre stage in this changing world, must adjust their relationships and partnerships to reduce the burden of illness and ensure that multifaceted care needs are all properly addressed. In rare diseases, this relationship between patients and professionals demands a new model of care, in which patients are active, valued partners in their own care and function not as ‘enlightened self-interested’ individuals but as experts by experience. The unique characteristics of rare diseases demand that care evolves beyond multidisciplinary team care to ‘Networked-care’, in which care is prescribed based upon the body of experience and expertise of a community of experts and patients (who are experts by experience). Healthcare models are being redrawn around a new norm of clinical practice based on true patient-clinical partnerships in care. A partnership with patients, when supported by proper investment, is a collaborative relationship that aligns both the medical and clinical perspectives of professionals with a holistic perspective of patients’ life experiences. Such partnerships can (i) ensure that decisions around care and design of services are needs-led, (ii) reduce the fog of uncertainty that surrounds rare diseases, (iii) amplify the success of new discoveries, and (iv) create breakthrough innovations: in these ways, patient-clinical partnerships increase the efficiency and effectiveness of our work and build a more sustainable future for our healthcare services.
Similar content being viewed by others
Notes
References
Armstrong MJ, Mullins CD, Gronseth GS, Gagliardi AR (2017) Recommendations for patient engagement in guideline development panels: a qualitative focus group study of guideline-naïve patients. PLoS One 12(3):e0174329. https://doi.org/10.1371/journal.pone.0174329
Brett J, Staniszewska S, Mockford C, Herron-Marx S, Hughes J, Tysall C, Suleman R (2014) Mapping the impact of patient and public involvement on health and social care research: a systematic review. Health Expect 17:637–650. https://doi.org/10.1111/j.1369-7625.2012.00795
Carman Kristin L, Dardess P, Maurer M, Sofaer S, Adams K, Bechtel C, Sweeney J (2013) Patient and family engagement: a framework for understanding the elements and developing interventions and policies, Health Affairs Journal Vol. 32, No. 2: New Era of Patient Engagement https://doi.org/10.1377/hlthaff.2012.1133
Chalmers JD, Timothy A, Polverino E, Almagro M, Ruddy T, Powell P, Boyd J (2017) Patient participation in ERS guidelines and research projects: the EMBARC experience. Breathe Sheff Engl 13(3):194–207. https://doi.org/10.1183/20734735.009517
Charmel PA, Frampton SB (2008) Building the business case for patient centered care. Healthc Financ Manage 62(3):80–85
Cornman DH, White CM (2017) Discerning the perception and impact of patients involved in evidence-based practice center key informant interviews [Internet]. Agency for Healthcare Research and Quality (US); Report No.: 17-EHC032-EF. AHRQ Methods for Effective Health Care
Coulter A, Ellins J (2007) Effectiveness of strategies for informing, educating, and involving patients. BMJ. 335(7609):24–27
Epstein R, Street R (2008) Patient-centered care for the 21st century: physicians’ roles, health systems and patients’ preferences. Philadelphia (PA). ABIM Foundation
EURORDIS (2017) Juggling care and daily life: The balancing act of the rare disease community. http://download2.eurordis.org.s3.amazonaws.com/rbv/2017_05_09_Social%20survey%20leaflet%20final.pdf. Accessed October 2020
Fønhus MS, Dalsbø TK, Johansen M, Fretheim A, Skirbekk H, Flottorp SA (2018) Patient-mediated interventions to improve professional practice. Cochrane Database Syst Rev. CD012472. doi: https://doi.org/10.1002/14651858.CD012472.pub2
Gupta D, Lis CG, Rodeghier M (2013) Can patient experience with service quality predict survival in colorectal cancer? J Healthc Qual 35:37–43
Gupta D, Rodeghier M, Lis CG (2014) Patient satisfaction with service quality as a predictor of survival outcomes in breast cancer. Support Care Cancer 22:129–134
Hedley V, Aymé S, Murray H, Rodwell C (2018) 2018 report on the state of the art of rare disease activities in Europe http://www.rd-action.eu/wp-content/uploads/2018/09/Final-Overview-Report-State-of-the-Art-2018-version.pdf Accessed 15 Nov 2020
Lynn S, Hedley V, Atalaia A, Evangelista T, Bushby K (2017) How the EUCERD joint action supported initiatives on rare diseases. European Journal of Medical Genetics 60(3):185–189. https://doi.org/10.1016/j.ejmg.2017.01.002
Menon D, Stafinski T, Dunn A, Short H (2015) Involving patients in reducing decision uncertainties around orphan and ultra-orphan drugs: a rare opportunity? The Patient - Patient-Centered Outcomes Research 8(1):29–39
Sharma AE, Knox M, Mleczko VL, Olayiwola JN (2017) The impact of patient advisors on healthcare outcomes: a systematic review. BMC Health Serv Res 17(1):693. https://doi.org/10.1186/s12913-017-2630-4
Tokhi M, Comrie-Thomson L, Davis J, Portela A, Chersich M, Luchters S (2018) Involving men to improve maternal and newborn health: a systematic review of the effectiveness of interventions. PLoS One 13(1):e0191620. https://doi.org/10.1371/journal.pone.0191620
Funding
The perspectives shared in this article do not originate from any particular project or funding opportunity. EURORDIS was/is a partner in the following projects (which are mentioned in the manuscript)
• Rare 2030 PP-1-2-2018-Rare 2030, co-funded by the European Union Pilot Projects and Preparatory Actions Programme
• RD-ACTION: ‘Data and Policies for Rare diseases’ 677024 which received funding from the European Union’s Third Health Program
• EUCERD Joint Action: Working for Rare Diseases (No. 2011 22 01) which received funding from the European Union’s Second Health Programme
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Ethical approval
This article does not discuss or contain any studies with human participants or animals performed by any of the authors.
Conflict of interest
The authors declare no competing interest.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This article is part of the Topical Collection on Rare Diseases
Rights and permissions
About this article
Cite this article
Bolz-Johnson, M., Kenny, T., Le Cam, Y. et al. Our greatest untapped resource: our patients. J Community Genet 12, 241–246 (2021). https://doi.org/10.1007/s12687-021-00524-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12687-021-00524-5